Market Place
Sourcing Support
Crossject Announces EUR 7.2M Capital Increase & Warrants Issuance
11 Dec 2024 //
GLOBENEWSWIRE
Crossject Launch 7M Reserved Capital Increase & Warrants Issuance
10 Dec 2024 //
GLOBENEWSWIRE
Crossject Demonstrates ZENEO® Auto-Injector Usability in HAZMAT
13 Nov 2024 //
GLOBENEWSWIRE
Crossject Reports Progress With Epilepsy Therapy ZEPIZURE®
22 Oct 2024 //
GLOBENEWSWIRE
Crossject Announces PEA-PME Investment Scheme Eligibility
26 Sep 2024 //
GLOBENEWSWIRE
Crossject Reports H1 2024 Financial Results And Highlights
23 Sep 2024 //
GLOBENEWSWIRE
Crossject to Report First-Half Results on September 23
17 Sep 2024 //
GLOBENEWSWIRE
Crossject to Present at the H.C. Wainwright 26th Annual Investment Conference
22 Aug 2024 //
GLOBENEWSWIRE
Crossject Appoints Tony Tipton As US COO For ZEPIZURE Commercialization
19 Aug 2024 //
GLOBENEWSWIRE
Crossject achieves key ZEPIZURE® manufacturing milestone
18 Jul 2024 //
GLOBENEWSWIRE
Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference
15 Jul 2024 //
GLOBENEWSWIRE
Crossject Gets 6.9M From French Government For ZENEO Epinephrine
10 Jul 2024 //
GLOBENEWSWIRE
Crossject Elaborates On ZEPIZURE Potential In Light Of RAMPART Study
26 Jun 2024 //
GLOBENEWSWIRE
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America
12 Jun 2024 //
GLOBENEWSWIRE
Crossject announces highly successful closing of its €8 million rights offering
04 Jun 2024 //
GLOBENEWSWIRE
Crossject Publishes ZEPIZURE® Clinical Data In Neurology Journal
30 May 2024 //
GLOBENEWSWIRE
Crossject Extends ZEPIZURE Commercialization Deal In Europe
02 May 2024 //
GLOBENEWSWIRE
Crossject reports audited financial results for 2023
25 Apr 2024 //
GLOBENEWSWIRE
Crossject advances in its U.S. Strategy and reports Financial Results for 2023
02 Apr 2024 //
GLOBENEWSWIRE
Crossject Trading on Euronext to Resume as Usual on Wednesday April 3
02 Apr 2024 //
GLOBENEWSWIRE
Crossject gender equality score reaches 96/100 in 2024
08 Mar 2024 //
GLOBENEWSWIRE
Crossject obtains a financing up to ‚¬12 million, in two tranches
27 Feb 2024 //
GLOBENEWSWIRE
Crossject provides strategic update on priorities for 2024
06 Feb 2024 //
GLOBENEWSWIRE
Crossject to host a business briefing on strategy on February 6 at 17:30 CET
01 Feb 2024 //
GLOBENEWSWIRE
Crossject to present at Biotech Showcase on January 9 at 16:30 PT
09 Jan 2024 //
GLOBENEWSWIRE
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
04 Jan 2024 //
GLOBENEWSWIRE
Crossject signs ZEPIZURE® commercialization agreement for northern Europe
22 Dec 2023 //
GLOBENEWSWIRE
Crossject announces initiation of coverage by ODDO BHF
28 Nov 2023 //
GLOBENEWSWIRE
Crossject reports financial results & business highlights for first half of 2023
26 Sep 2023 //
GLOBENEWSWIRE
Crossject announces significant improvement in Gaïa ESG rating
11 Sep 2023 //
GLOBENEWSWIRE
Crossject reports completion of audits for manufacturing of ZENEO® Midazolam
05 Sep 2023 //
GLOBENEWSWIRE
Crossject signs agreement on ZENEO Midazolam epilepsy rescue therapy with AFT
20 Jul 2023 //
GLOBENEWSWIRE
Crossject - Appointment of Daniel Teper to the Crossject Supervisory Board
01 Jun 2023 //
GLOBENEWSWIRE
Crossject - 2022 Annual Results
21 Mar 2023 //
GLOBENEWSWIRE
Crossject - 2022 Annual Results
20 Mar 2023 //
GLOBENEWSWIRE
CROSSJECT - CLINICAL DEMONSTRATION OF ZENEO® EFFICIENCY FOR INTRAMUSCULAR INJ
01 Nov 2022 //
GLOBENEWSWIRE
